Transdermal patches of buprenorphine (10mg) and diclofenac (200mg) for of post-operative analgesia: adverse effects and patient satisfactionDr.Neeta Kulkarni,Dr.Lokesh SB,Dr.Geetha M.
Buprenorphine is a highly lipophilic semisynthetic opioid.it is derived from thebaine, a morphine opioid.
Buprenorphine is a partial agonist at μ opioid receptors which has high affinity but moderate intrinsic
activity. Buprenorphine is also an antagonist at kappa-opioid receptors and delta -opioid receptors, and a
partial agonist at ORL-1 (nociceptin) receptors. Following ethics committee approval, informed written
consent was obtained from the patients. Detailed pre-anaesthetic evaluation was done. Demographic
(age, gender), morphological (height, weight) and vital parameters were recorded. In our study 7 patients
in Buprenorphine group had nausea/vomiting and one patient was drowsy but arousable whereas in
Diclofenac group 4 patients had nausea and none of the patients were sedated during the entire study
Key words: Transdermal patches, buprenorphine, diclofenac